# Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

> **NCT01987739** · PHASE1 · COMPLETED · sponsor: **Midnight Pharma, LLC** · enrollment: 42 (actual)

## Conditions studied

- Abuse Potential Study

## Interventions

- **DRUG:** 200 mg almorexant
- **DRUG:** 400 mg almorexant
- **DRUG:** 1000 mg almorexant
- **DRUG:** 20 mg zolpidem
- **DRUG:** 40 mg zolpidem
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01987739
- **Lead sponsor:** Midnight Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2016-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01987739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01987739, "Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT01987739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*